These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22883365)

  • 21. 2010 FIFA world cup South Africa: travel health issues and new options for protection against meningococcal disease.
    Zuckerman JN; Bröker M; Worth C
    Travel Med Infect Dis; 2010 Mar; 8(2):68-73. PubMed ID: 20478511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meningococcal meningitis.
    Aguado T; Bertherat E; Djingarey M; Kandolo D; Kieny MP; Kondé K; LaForce FM; Nelson CB; Perea W; Préziosi MP
    Nat Rev Microbiol; 2005 Jan; 3(1):10-1. PubMed ID: 15635779
    [No Abstract]   [Full Text] [Related]  

  • 23. [
    Boccalini S; Panatto D; Mennini FS; Marcellusi A; Bini C; Amicizia D; Lai PL; Micale RT; Frumento D; Azzari C; Ricci S; Bonito B; DI Pisa G; Iovine M; Lodi L; Giovannini M; Moscadelli A; Paoli S; Pennati BM; Pisano L; Bechini A; Bonanni P
    J Prev Med Hyg; 2021 Mar; 62(1 Suppl 1):E1-E128. PubMed ID: 34622076
    [No Abstract]   [Full Text] [Related]  

  • 24. Few university students from overseas have been vaccinated against meningococcal infection.
    Edmunds MR; Davidson JE; Wood AL; Raichura V
    BMJ; 2001 Jan; 322(7278):102. PubMed ID: 11154644
    [No Abstract]   [Full Text] [Related]  

  • 25. Supplementary statement on conjugate meningococcal vaccines.
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2003 Sep; 29():10-1. PubMed ID: 14526693
    [No Abstract]   [Full Text] [Related]  

  • 26. Meningococcal C conjugate vaccination recommendations for infants. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 Nov; 33(ACS-11):1-12. PubMed ID: 18064747
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine evaluation: lessons from a meningococcal B vaccine.
    Sarfatti A; Martinón-Torres F; Nadel S
    Arch Dis Child; 2015 Jun; 100(6):514-6. PubMed ID: 25670403
    [No Abstract]   [Full Text] [Related]  

  • 29. [Survey on vaccination strategies used in different Italian Regions, for the 7-valent conjugate pneumococcal, meningococcal C and varicella vaccines].
    D'Ancona F; Alfonsi V; Ciofi degli Atti ML
    Ig Sanita Pubbl; 2006; 62(5):483-92. PubMed ID: 17206224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pros and cons of vaccination against serogroup B meningococcal disease.
    Delgado Rodríguez M; Domínguez García Á
    Med Clin (Barc); 2018 Feb; 150(3):109-113. PubMed ID: 28992986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reply to: Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact.
    Wassil J; Huels J; Narasimhan V
    Vaccine; 2014 May; 32(25):2943. PubMed ID: 23962533
    [No Abstract]   [Full Text] [Related]  

  • 32. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.
    Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM
    Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningococcal vaccine: a position statement of the society for adolescent health and medicine.
    Ipp LS; Breuner CC; Middleman AB;
    J Adolesc Health; 2012 Feb; 50(2):211-2. PubMed ID: 22265123
    [No Abstract]   [Full Text] [Related]  

  • 34. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meningococcal vaccines: a neglected topic in travel medicine?
    Wilder-Smith A
    Expert Rev Vaccines; 2009 Oct; 8(10):1343-50. PubMed ID: 19803757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.
    Welte R; Trotter CL; Edmunds WJ; Postma MJ; Beutels P
    Pharmacoeconomics; 2005; 23(9):855-74. PubMed ID: 16153131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunisation against meningococcus B.
    Eskola J
    Lancet; 2013 Sep; 382(9897):1019. PubMed ID: 24054532
    [No Abstract]   [Full Text] [Related]  

  • 38. Indirect effects by meningococcal vaccines: herd protection versus herd immunity.
    Bröker M
    Hum Vaccin; 2011 Aug; 7(8):881-2. PubMed ID: 21785283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):273. PubMed ID: 20224545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.
    Trotter CL; Ramsay ME
    FEMS Microbiol Rev; 2007 Jan; 31(1):101-7. PubMed ID: 17168998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.